1 – 4 of 4
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Bivalirudin versus heparin in ST and non-ST-segment elevation myocardial infarction—Outcomes at two years
(
- Contribution to journal › Article
- 2021
-
Mark
Bivalirudin Versus Heparin Monotherapy in ST-Segment-Elevation Myocardial Infarction
(
- Contribution to journal › Article
- 2018
-
Mark
No benefit of ticagrelor pretreatment compared with treatment during percutaneous coronary intervention in patients with ST-segment⇓elevation myocardial infarction undergoing primary percutaneous coronary intervention
(
- Contribution to journal › Article
- 2017
-
Mark
Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction
(
- Contribution to journal › Article